Carregant...
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
A desirable property of any dose-escalation strategy for phase I oncology trials is coherence: if the previous patient experienced a toxicity, a higher dose is not recommended for the next patient; similarly, if the previous patient did not experience a toxicity, a lower dose is not recommended for...
Guardat en:
| Publicat a: | Stat Pap (Berl) |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5985932/ https://ncbi.nlm.nih.gov/pubmed/29875549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00362-016-0790-7 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|